Overview

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
3-Iodobenzylguanidine